ANIX Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
2.6M
-2.5%
2.7M
-5.6%
2.9M
+18.1%
2.4M
-18.9%
3.0M
R&D
1.3M
+14.2%
1.1M
-3.5%
1.1M
+8.2%
1.1M
-20.2%
1.3M
SG&A
1.4M
-13.9%
1.6M
-6.9%
1.7M
+25.6%
1.4M
-17.8%
1.7M
Operating Income
-2647000
+2.5%
-2716000
+5.6%
-2876000
-18.1%
-2436000
+18.9%
-3003000
EBITDA
-2647000
+2.5%
-2716000
+5.6%
-2876000
-18.1%
-2436000
+18.9%
-3003000
Net Income
-2536000
+1.9%
-2585000
+5.0%
-2722000
-19.4%
-2280000
+18.9%
-2813000
EPS (Basic)
$-0.07
+12.5%
$-0.08
+0.0%
$-0.08
-14.3%
$-0.07
+22.2%
$-0.09
EPS (Diluted)
$-0.07
+12.5%
$-0.08
+0.0%
$-0.08
-14.3%
$-0.07
+22.2%
$-0.09
Shares (Diluted)
33.6M
+1.1%
33.2M
+0.9%
32.9M
+1.4%
32.5M
+0.9%
32.2M
Anixa Biosciences (ANIX) โ€” Financials